Foreign drug firms in China see approval delays

Beijing

FOREIGN pharmaceutical companies in China say they are concerned that recent regulatory delays could push back plans to introduce their newest medicines into the country by as many as two years.

At least thirty-four applications from foreign multinationals have been or are set to be delayed after Chinese regulators began requiring an added procedure, according to R&D- Based Pharmaceutical Association Committee, an industry group.